Comparing the current results to its competitors, Protara Therapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 7.74 %, recorded in the same quarter.
Protara Therapeutics Inc, slower than the average decrease reported by the company's competitors of -49.19 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -49.19 %
Protara Therapeutics Inc's Comment on Competition and Industry Peers
The company operates in a competitive global pharmaceutical and biotechnology market, facing competition from other firms as well as from generic and biosimilar products. Competitors may develop or market therapies that become available earlier, demonstrate greater clinical effectiveness, offer improved safety, or are less costly than the company's therapeutic products. Multiple companies are involved in the development, patenting, manufacturing, and marketing of healthcare products that compete with those under development by the company. The company's lead product candidate, TARA-002, contains a genetically distinct strain of Streptococcus pyogenes (group A, type 3) Su strain. The competitive environment also includes potential generic competitors who may submit abbreviated new drug applications (ANDAs) based on drugs listed in the FDA's Orange Book, enabling the marketing of generic equivalents without new preclinical or clinical testing.
November 15, 2024
Protara Therapeutics Unveils Promising Interim Results for TARA-002 in NMIBC at Prestigious Oncology Meeting Amidst the gathering of leading experts and trailblazers at the 25th Annual Meeting of the Society of Urologic Oncology (SUO) in Dallas, Texas, Protara Therapeutics, Inc. (Nasdaq: TARA) is set to make a compelling presentation regarding their latest findings on TARA-002, an innovative treatment for non-muscle invasive bladder cancer (NMIBC). Scheduled for December 4 to December 6, 2024, the event marks a pivotal moment for this clinical-stage company, which is dedicated to pioneering transformative therapies for cancer and rare diseases.As the enthusiasm builds, Protara has released intriguing details...
September 9, 2024
Protara Therapeutics Presents Groundbreaking Insights from THRIVE-1 Study on Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support at ESPEN Conference NEW YORK, Sept. 09, 2024 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company at the forefront of developing transformative therapies for cancer and rare diseases, has unveiled key findings from its THRIVE-1 study. This prospective, observational study investigated the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS). These promising results were presented during a poster session at the 46th European Society for Clinical Nutrition and Metabolism Congress (ESPEN), held ...
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Sources:
Protara Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Protara Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
